Metaraminol Laboratoire Aguettant

Metaraminol, the active ingredient in Metaraminol Laboratoire Aguettant, is a sympathomimetic vasopressor presented as an injectable solution for intravenous use. It is employed to treat acute hypotension, shock, and anesthesia‑induced blood pressure drops in hospital settings.

GNH USA supplies Metaraminol Laboratoire Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metaraminol acts as a direct alpha‑1 adrenergic agonist to raise systemic vascular resistance in conditions associated with low blood pressure.

- Hypotension: restores arterial pressure during peri‑operative or critical‑care hypotension. - Cardiogenic shock: supports circulatory function when cardiac output is insufficient. - Septic shock: augments vascular tone in distributive shock states. - Anesthesia‑induced hypotension: maintains hemodynamic stability during surgical procedures.

Metaraminol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often related to rapid blood pressure changes. - Tachycardia: increased heart rate due to reflex mechanisms. - Hypertension: overshoot of blood pressure if dosing is excessive. - Nausea: gastrointestinal discomfort reported by some patients. - Anxiety: nervousness or restlessness during infusion. - Flushing: transient skin redness.

Serious or Rare Side Effects: - Arrhythmias: potentially life‑threatening irregular heart rhythms. - Myocardial ischemia: reduced coronary blood flow leading to chest pain. - Severe hypertension: dangerous spikes in blood pressure. - Tissue necrosis at injection site: local tissue damage if extravasation occurs. - Pulmonary edema: fluid accumulation in the lungs. - Anaphylaxis: rare severe allergic reaction requiring immediate intervention.

Metaraminol requires careful clinical monitoring and adherence to safety guidelines.

- Cardiovascular monitoring: continuous blood pressure and heart‑rate observation is essential. - Dose titration: adjust infusion slowly to avoid abrupt hypertension. - Renal impairment: use with caution and monitor renal function. - Pregnancy: safety not established; weigh potential benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Metaraminol can interact with other agents that affect vascular tone or cardiac function.

Major Interactions (Avoid): - MAO inhibitors: additive hypertensive response may be severe. - Indirect sympathomimetics (e.g., ephedrine): risk of excessive vasoconstriction. - Tricyclic antidepressants: potentiation of pressor effects.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitroglycerin): may blunt therapeutic pressor response. - Anesthetic agents (e.g., halothane): can alter hemodynamic stability. - Calcium channel blockers: may require dose adjustments to maintain target blood pressure.